Business Description
Resverlogix Corp
NAICS : 325410
SIC : 3741
ISIN : CA76128M1086
Total Employee Number:
18Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -11.3 | |||||
Debt-to-Equity | -0.24 | |||||
Debt-to-EBITDA | -22.44 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -44.2 | |||||
3-Year EPS without NRI Growth Rate | 5.7 | |||||
3-Year FCF Growth Rate | 1.5 | |||||
3-Year Book Growth Rate | -12.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.49 | |||||
9-Day RSI | 49.11 | |||||
14-Day RSI | 48.02 | |||||
3-1 Month Momentum % | -8.26 | |||||
6-1 Month Momentum % | -4.31 | |||||
12-1 Month Momentum % | 141.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -33.17 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -78.46 | |||||
ROIC % | -20.63 | |||||
3-Year ROIIC % | 49.88 | |||||
ROC (Joel Greenblatt) % | -16434.78 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -31.44 | |||||
EV-to-EBITDA | -44.58 | |||||
EV-to-FCF | -9.86 | |||||
Earnings Yield (Greenblatt) % | -3.18 | |||||
FCF Yield % | -21.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Resverlogix Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.018 | ||
| Beta | 2.0157 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.57 | ||
| Volatility % | 129.55 | ||
| 14-Day RSI | 48.02 | ||
| 14-Day ATR (€) | 0.002171 | ||
| 20-Day SMA (€) | 0.05385 | ||
| 12-1 Month Momentum % | 141.3 | ||
| 52-Week Range (€) | 0.0245 - 0.158 | ||
| Shares Outstanding (Mil) | 316.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Resverlogix Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Resverlogix Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 47 days | ||
| General meeting for 2026 | 2026-06-25 15:00 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.05 (+0.00%) | ||
| Annual report for 2025 | 2026-04-10 | 0.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-10 | 0.06 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.06 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.07 (+0.00%) | ||
| General meeting for 2025 | 2025-06-30 13:00 | 0.02 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.03 (+0.00%) |
Show
Entries
Resverlogix Corp Frequently Asked Questions
What is Resverlogix Corp(FRA:RFS)'s stock price today?
The current price of FRA:RFS is €0.05. The 52 week high of FRA:RFS is €0.16 and 52 week low is €0.02.
When is next earnings date of Resverlogix Corp(FRA:RFS)?
The next earnings date of Resverlogix Corp(FRA:RFS) is 2026-08-14 Est..
Does Resverlogix Corp(FRA:RFS) pay dividends? If so, how much?
Resverlogix Corp(FRA:RFS) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX) | 2019-04-11 |
Articles on Resverlogix Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers